Previous research has suggested that antibiotics may increase the risk of developing inflammatory bowel disease and autoimmune diseases such as type 1 diabetes and autoimmune liver disease, so researchers decided to asses if antibiotic use is associated with the onset of rheumatoid arthritis.1
Microbiota or bacteria, live in various parts of the human body including the skin (skin microbiota), the mouth (oral microbiota) and the intestinal tract (gut microbiota). Our intestines contain tens of trillions of microorganisms including more than 1000 different types of bacteria. These microorganisms play and integral part in keeping our metabolism and immune system functioning at its peak.
Antibiotic usage can lead to a significant reduction in the type of microbial in our gut and the overall total number of microbials in our gut, directly impacting our metabolism and immune system.
To evaluate if antibiotic use was associated with the development of rheumatoid arthritis (RA), researchers at the Quadram Institute on the Norwich Research Park, conducted a case-controlled study using data from the primary care Clinical Practice Research Datalink in the UK. Researchers analyzed data from more than 22,600 people diagnosed with RA 90,000 healthy individuals. The results showed people who had received a prescription for one treatment with antibiotics had a 40 percent greater chance of developing RA, those who had received two prescriptions for antibiotics had a 66 percent greater chance of developing RA and the odds continued to increase for those individuals who had received three or four courses of antibiotic treatment.
Individuals who had taken antibiotics within the past 1-2 years had 80% greater odds of developing RA.
Stem Cell Therapy for RA at the Stem Cells Transplant Institute
Researchers are focusing on developing treatment options that will not only treat the symptoms associated with rheumatoid arthritis, but ultimately repair and replace the damaged tissue and reduce inflammation, preventing future tissue damage.
Physicians are studying the safety and efficacy of mesenchymal stem cells because of their ability to suppress the immune system, reduce inflammation, and repair tissue.3,4
Stem cell therapy for rheumatoid arthritis has been found to be safe.4,5 Two clinical trials evaluated the efficacy of mesenchymal stem cells in 225 patients with rheumatoid arthritis. Results showed patients treated with mesenchymal stem cells did better than patients in the control arms. Patients treated with mesenchymal stem cells had beneficial reductions in their symptoms of rheumatoid arthritis.4,6,7
Research is showing hUC-MSCs to be a better alternative to allogeneic stem cells because of their hypo-immunogenicity, superior tropism, high differentiation potential and paracrine activity.2,3
What are the advantages of human umbilical cord mesenchymal stem cells?
- Abundant supply containing up to 10 times more stem cells than bone marrow or adipose derived stem cells
- hUC-MSC have immunosuppressors and immunomodulatory properties that allow their use in any individual without rejection- Human Leukocyte Antigen (HLA) matching is not necessary
- Greater proliferation ability than adult autologous stem cells
- They regenerate at a very rapid rate
- They are young and very adaptive
- They have not been impacted by the aging process
- They have not been affected by environmental toxins
- Umbilical cord stem cells can be administered multiple times over the course of days
- Eliminates the need to collect stem cells from the patient’s fat or hip bone reducing pain and recovery time
What is the recommended treatment protocol for rheumatoid arthritis at the Stem Cells Transplant Institute?
The Stem Cells Transplant Institute recommends the use of hUC-MSCs for the treatment of RA. For optimal results, we recommend a two-day treatment. Each day you will receive the following:
- 1cc vial of 120 million mesenchymal stem cells derived from human umbilical cord blood
- Antioxidant therapy with vitamin C and glutathione
- Ozone therapy
- Platelet-rich plasma therapy (PRP)
- Alyshah Abdul Sultan, Christian Mallen, Sara Muller, Samatha Hider, Ian Scott, Toby Helliwell & Lindsey J. Hall. Antibiotic use and the risk of rheumatoid arthritis: a population-based case-control study. BMC Medicine, 17, Article number: 154 (2019).
- Kim, J. Y., Jeon, H. B., Yang, Y. S., Oh, W. & Chang, J. W. Application of human umbilical cord blood-derived mesenchymal stem cells in disease models. World J Stem Cells2, 34–8 (2010).
- Jeong, S. Y. et al. Thrombospondin-2 secreted by human umbilical cord blood-derived mesenchymal stem cells promotes chondrogenic differentiation. Stem Cells31, 2136–48 (2013).
- A.G. Kay et al. Chapter 8 Mesenchymal Stem Cell Therapy in Rheumatoid ArthritisP. Van Pham (ed.), Bone and Cartilage Regeneration, Stem Cells in Clinical Applications,149-176.
- Iyer SS, Rojas M. Anti-infl ammatory effects of mesenchymal stem cells: novel concept for future therapies. Expert Opin Biol Ther. 2008;8(5):569–81.
- Alvaro-Gracia JM, Jover JA, Garcia-Vicuña R, Carreño L, Alonso A, Marsal S, et al. Phase IB/Iia study on intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis patients (abstract). Arthritis Rheum. 2013;65(Suppl 10):2644. doi:10.1002/art.2013.65.issue-s10.
- Wang L, et al. Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy. Stem Cells Dev. 2013;22(24):3192–202. doi:10.1089/ scd.2013.0023.